Syntekabio to Showcase Biologics Discovery Platform at PEGS Boston
May 07 2024 - 10:30AM
Syntekabio (226330.KQ), a global artificial intelligence (AI) drug
discovery pioneer, today announced its participation at the 20th
Annual PEGS Boston – The Essential Protein & Antibody
Engineering Summit, where the company will highlight its novel
biologics platform. The event is being held May 13-17, 2024 at the
Omni Hotel at the Seaport, Boston, MA.
Following the recent launch of its AI-driven
drug discovery services in the US and Europe and the rollout of STB
LaunchPad, Syntekabio's versatile technology platform for small
molecule drug candidate generation, the company is excited to
showcase its in-silico biologics discovery capabilities with
Neo-ARS, its cutting-edge AI platform for personalized or universal
neoantigen prediction, so-called tumor-specific cancer vaccines, as
well as Ab-ARS for the prediction of novel
complementarity-determining regions (CDRs) of antibody heavy
chains.
Jonathan Witztum, PhD, Chief Technology Officer
at Syntekabio USA Inc., commented: “PEGS Boston is an excellent
platform for us to present our in-silico biologics platform and our
comprehensive set of AI-driven solutions for drug discovery. We
look forward to engaging with leading biologics experts and
discussing how our innovative technologies can positively impact
therapeutics development and help to bring novel, highly effective
solutions to patients.”
Neo-ARS was developed in partnership with
Chungnam National University Hospital, Korea and already has shown
promising results in identifying and evaluating cancer neoantigens
for acute myeloid leukemia (AML), demonstrating its potential in
personalized immunotherapy.
In a strategic move to bring these advancements
to patients, Syntekabio has partnered with Metaclipse Therapeutics,
a US biotechnology company developing immunotherapies for cancer
and vaccines for infectious disease. The companies have signed a
memorandum of understanding to initiate a joint research project,
which will utilize Neo-ARS to identify highly immunogenic
neoantigens, critical for the development of effective cancer
vaccines and personalized immunotherapies.
Ab-ARS and Neo-ARS facilitate rapid antibody
prediction and optimization by leveraging a vast hydrogen-bonded
peptide-peptide interaction database, as well as AI-driven 3D
modeling. This is complemented by phage display experiments.
Antibody heavy chains predicted by this technology, as well as
personalized neoantigen-driven immunogenicity, can be used upstream
to innovative therapeutic antibody designs, including bispecific
T-cell engagers, multi-specific antibodies, and nanobodies.
20th Annual PEGS Boston – The Essential
Protein & Antibody Engineering SummitMay 13-17,
Boston, MA, USAEngage with Syntekabio’s Innovators at Booth
40Don't miss the opportunity to meet with Syntekabio's
team at Booth 40 to learn how the company’s services can find
solutions to solve pipeline challenges, fast.
About Syntekabio
Syntekabio Co., Ltd. (KOSDAQ: 226330) is a drug
discovery company bringing together biology and AI/ML since 2009
and facilitating the discovery of first-in-class and best-in-class
compounds, rapidly. The company has its own supercomputer cloud,
along with a global contract research organization network to
complement and validate its computational results. Syntekabio
offers clients a one-stop shop, with technologies and tailored
services to rapidly generate and optimize drug candidates from
target to IND-enabling. Syntekabio’s disease-agnostic platform
generates a continual stream of hits, leads, and drug candidates
that are readily available for purchase. The company also
undertakes client-specific projects to identify highly promising
development candidates for specific targets and indications.
Contact
Media inquiries – US &
Europe:
MC Services AGEurope: Dr. Cora Kaiser+49
89 210 228 0US: Laurie Doyle+1 339 832 0752
syntekabio@mc-services.eu